BioSight
Companies
Silence Therapeutics plc logo

SLN

NASDAQLONDON
Silence Therapeutics plc

Silence Therapeutics develops drug candidates using RNA interference (RNAi) technology to treat genetic and inflammatory diseases. The pipeline is in clinical and preclinical stages of development across multiple therapeutic areas. Silencers Therapeutics is advancing toward regulatory filings and commercialization while seeking to establish partnerships and maintain intellectual property protection for its product candidates.

Price history not yet available for SLN.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar